Correcting Postprandial Hyperglycemia in Zucker Diabetic Fatty Rats With an SGLT2 Inhibitor Restores Glucose Effectiveness in the Liver and Reduces Insulin Resistance in Skeletal Muscle

Overview

Journal Diabetes

Specialty Endocrinology

Date 2017 Mar 2

PMID 28246292

Citations 27

Authors

Tracy P OBrien

Erin C Jenkins

Shanea K Estes

Antonio V Castaneda

Kiichiro Ueta

Tiffany D Farmer

Allison E Puglisi

Larry L Swift

Richard L Printz

Masakazu Shiota

Affiliations

Soon will be listed here.

Abstract

Ten-week-old Zucker diabetic fatty (ZDF) rats at an early stage of diabetes embody metabolic characteristics of obese human patients with type 2 diabetes, such as severe insulin and glucose intolerance in muscle and the liver, excessive postprandial excursion of plasma glucose and insulin, and a loss of metabolic flexibility with decreased lipid oxidation. Metabolic flexibility and glucose flux were examined in ZDF rats during fasting and near-normal postprandial insulinemia and glycemia after correcting excessive postprandial hyperglycemia using treatment with a sodium-glucose cotransporter 2 inhibitor (SGLT2-I) for 7 days. Preprandial lipid oxidation was normalized, and with fasting, endogenous glucose production (EGP) increased by 30% and endogenous glucose disposal (E-Rd) decreased by 40%. During a postprandial hyperglycemic-hyperinsulinemic clamp after SGLT2-I treatment, E-Rd increased by normalizing glucose effectiveness to suppress EGP and stimulate hepatic glucose uptake; activation of glucokinase was restored and insulin action was improved, stimulating muscle glucose uptake in association with decreased intracellular triglyceride content. In conclusion, SGLT2-I treatment improves impaired glucose effectiveness in the liver and insulin sensitivity in muscle by eliminating glucotoxicity, which reinstates metabolic flexibility with restored preprandial lipid oxidation and postprandial glucose flux in ZDF rats.

Citing Articles

Recent advances in understanding the mechanisms in skeletal muscle of interaction between exercise and frontline antihyperglycemic drugs.

Newsom S, Robinson M Physiol Rep. 2024; 12(11):e16093.

PMID: 38845596 PMC: 11157199. DOI: 10.14814/phy2.16093.

The impact of glucagon to support postabsorptive glucose flux and glycemia in healthy rats and its attenuation in male Zucker diabetic fatty rats.

Estes S, Shiota C, OBrien T, Printz R, Shiota M Am J Physiol Endocrinol Metab. 2024; 326(3):E308-E325.

PMID: 38265288 PMC: 11193518. DOI: 10.1152/ajpendo.00192.2023.

Short-term recovery of insulin secretion in response to a meal is associated with future glycemic control in type 2 diabetes patients.

Enkaku A, Chujo D, Kamigishi M, Inagawa S, Matsukoshi S, Sakai W J Diabetes Investig. 2023; 15(4):437-448.

PMID: 38151917 PMC: 10981139. DOI: 10.1111/jdi.14129.

SGLT2 Inhibitors: A Broad Impact Therapeutic Option for the Nephrologist.

Granata A, Pesce F, Iacoviello M, Anzaldi M, Amico F, Catalano M Front Nephrol. 2023; 2:867075.

PMID: 37674992 PMC: 10479658. DOI: 10.3389/fneph.2022.867075.

Experimental Models to Study Diabetes Mellitus and Its Complications: Limitations and New Opportunities.

Martin-Carro B, Donate-Correa J, Fernandez-Villabrille S, Martin-Virgala J, Panizo S, Carrillo-Lopez N Int J Mol Sci. 2023; 24(12).

PMID: 37373455 PMC: 10299511. DOI: 10.3390/ijms241210309.

References

Brown K, Kalinowski S, Megill J, Durham S, Mookhtiar K . Glucokinase regulatory protein may interact with glucokinase in the hepatocyte nucleus. Diabetes. 1997; 46(2):179-86. DOI: 10.2337/diab.46.2.179. View

Lu M, Wan M, Leavens K, Chu Q, Monks B, Fernandez S . Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat Med. 2012; 18(3):388-95. PMC: 3296881. DOI: 10.1038/nm.2686. View

Gabbay R, Sutherland C, Gnudi L, Kahn B, OBrien R, GRANNER D . Insulin regulation of phosphoenolpyruvate carboxykinase gene expression does not require activation of the Ras/mitogen-activated protein kinase signaling pathway. J Biol Chem. 1996; 271(4):1890-7. DOI: 10.1074/jbc.271.4.1890. View

Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R . Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes. 2016; 65(5):1190-5. DOI: 10.2337/db15-1356. View

Shiota M . Measurement of glucose homeostasis in vivo: combination of tracers and clamp techniques. Methods Mol Biol. 2012; 933:229-53. DOI: 10.1007/978-1-62703-068-7_15. View

Shulman G . Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. 2014; 371(23):2237-8. DOI: 10.1056/NEJMc1412427. View

Nomura S, Sakamaki S, Hongu M, Kawanishi E, Koga Y, Sakamoto T . Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem. 2010; 53(17):6355-60. DOI: 10.1021/jm100332n. View

Ueta K, OBrien T, McCoy G, Kim K, Healey E, Farmer T . Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity. Am J Physiol Endocrinol Metab. 2014; 306(11):E1225-38. PMC: 4042096. DOI: 10.1152/ajpendo.00507.2013. View

Fujimoto Y, Donahue E, Shiota M . Defect in glucokinase translocation in Zucker diabetic fatty rats. Am J Physiol Endocrinol Metab. 2004; 287(3):E414-23. DOI: 10.1152/ajpendo.00575.2003. View

10.

Rossetti L, Giaccari A, DeFronzo R . Glucose toxicity. Diabetes Care. 1990; 13(6):610-30. DOI: 10.2337/diacare.13.6.610. View

11.

Mevorach M, Giacca A, Aharon Y, Hawkins M, Shamoon H, Rossetti L . Regulation of endogenous glucose production by glucose per se is impaired in type 2 diabetes mellitus. J Clin Invest. 1998; 102(4):744-53. PMC: 508937. DOI: 10.1172/JCI2720. View

12.

Ludvik B, Nolan J, Roberts A, Baloga J, Joyce M, Bell J . Evidence for decreased splanchnic glucose uptake after oral glucose administration in non-insulin-dependent diabetes mellitus. J Clin Invest. 1997; 100(9):2354-61. PMC: 508433. DOI: 10.1172/JCI119775. View

13.

Hawkins M, Gabriely I, Wozniak R, Reddy K, Rossetti L, Shamoon H . Glycemic control determines hepatic and peripheral glucose effectiveness in type 2 diabetic subjects. Diabetes. 2002; 51(7):2179-89. DOI: 10.2337/diabetes.51.7.2179. View

14.

Considine R, Nyce M, Allen L, Morales L, Triester S, Serrano J . Protein kinase C is increased in the liver of humans and rats with non-insulin-dependent diabetes mellitus: an alteration not due to hyperglycemia. J Clin Invest. 1995; 95(6):2938-44. PMC: 295982. DOI: 10.1172/JCI118001. View

15.

Madsbad S . Impact of postprandial glucose control on diabetes-related complications: How is the evidence evolving?. J Diabetes Complications. 2015; 30(2):374-85. DOI: 10.1016/j.jdiacomp.2015.09.019. View

16.

Kamata K, Mitsuya M, Nishimura T, Eiki J, Nagata Y . Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure. 2004; 12(3):429-38. DOI: 10.1016/j.str.2004.02.005. View

17.

Monica Reddy R, Inzucchi S . SGLT2 inhibitors in the management of type 2 diabetes. Endocrine. 2016; 53(2):364-72. DOI: 10.1007/s12020-016-0943-4. View

18.

Chibalin A, Leng Y, Vieira E, Krook A, Bjornholm M, Long Y . Downregulation of diacylglycerol kinase delta contributes to hyperglycemia-induced insulin resistance. Cell. 2008; 132(3):375-86. DOI: 10.1016/j.cell.2007.12.035. View

19.

Groop L, Bonadonna R, DelPrato S, Ratheiser K, Zyck K, Ferrannini E . Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest. 1989; 84(1):205-13. PMC: 303971. DOI: 10.1172/JCI114142. View

20.

Torres T, Fujimoto Y, Donahue E, Printz R, Houseknecht K, Treadway J . Defective glycogenesis contributes toward the inability to suppress hepatic glucose production in response to hyperglycemia and hyperinsulinemia in zucker diabetic fatty rats. Diabetes. 2011; 60(9):2225-33. PMC: 3161317. DOI: 10.2337/db09-1156. View